Sign in
Active, not recruitingNo phase

Diagnostic Performance of Urinary CD163 as a Non-invasive Biomarker for Egyptian Lupus Nephritis Patients Versus Conventional Biomarkers

Key facts

Who runs it
Assiut University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
50 people, planned
Started
1 Oct 2026
Expected to end
1 Feb 2028
Type of study
Observational, 3 groups
Record updated
12 November 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged 18 years or older
  • Diagnosis of systemic lupus erythematosus (SLE) according to the 2019 ACR/EULAR classification criteria
  • Diagnosis of lupus nephritis according to the ACR criteria
  • Biopsy-proven lupus nephritis
  • Adequate renal biopsy tissue available for histopathological classification and assessment of activity and chronicity indices
  • Active lupus nephritis requiring induction or escalation of immunosuppressive treatment
  • Availability of baseline laboratory investigations
  • Ability to provide a urine sample for urinary soluble CD163 measurement

Who cannot take part

  • Previous kidney transplantation
  • Chronic kidney disease unrelated to systemic lupus erythematosus
  • Recent infection or acute inflammatory condition
  • Active urinary tract infection at the time of urine sampling
  • Severe infection requiring hospitalization or intravenous antimicrobial treatment at baseline
  • Malignancy or another major inflammatory disease that could significantly affect urinary CD163 levels
  • Inadequate renal biopsy specimen for histopathological assessment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

kidney damage. Monitoring disease activity and predicting treatment response remain challenging because conventional laboratory markers may not always accurately reflect ongoing kidney inflammation.

Read full original descriptionShow less

This prospective observational study aims to evaluate the potential of urinary soluble CD163 (uCD163) as a non-invasive biomarker for predicting renal remission in patients with lupus nephritis. The study will investigate the relationship between urinary CD163 levels, clinical and laboratory parameters, and kidney biopsy findings. Serial urinary CD163 measurements will be performed during a six-month follow-up period to assess their association with changes in disease activity and response to standard immunosuppressive treatment.

The study may help determine whether urinary CD163 can provide additional information for monitoring lupus nephritis and predicting treatment outcomes.

The 3 groups in the trial

  • Group (I): 30 participants

    Group (I): 30 participants with histologically proven class III, IV, V or any combination of these classes of active LN.

  • Group (II): 10 patients

    Group (II): 10 patients with active SLE (SLEDAI \> 6) without nephritis confirmed by the absence of albuminuria or microscopic haematuria

  • Group (III): 10 patients

    Group (III): 10 participants with non-active SLE (SLEDAI score \<2).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
12 November 2026